Monte Rosa Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
07/08/2025 18:51
Monte Rosa Therapeutics Inc GLUE.OQ reported a quarterly adjusted loss of 15 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -43 cents. The mean expectation of eight analysts for the quarter was for a loss of 39 cents per share. Wall Street expected results to range from -51 cents to -21 cents per share. Revenue rose 394% to $23.19 million from a year ago; analysts expected $10.80 million. Monte Rosa Therapeutics Inc's reported EPS for the quarter was a loss of 15 cents. The company reported a quarterly loss of $12.3 million. Monte Rosa Therapeutics Inc shares had fallen by 3.4% this quarter and lost 37.2% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had fallen by about 7.1% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Monte Rosa Therapeutics Inc is $17.00, about 74.4% above its last closing price of $4.36 This summary was machine generated from LSEG data August 7 at 05:50 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.39 | -0.15 | Beat |
| Mar. 31 2025 | -0.34 | 0.56 | Beat |
| Dec. 31 2024 | -0.02 | 0.23 | Beat |
| Sep. 30 2024 | -0.49 | -0.29 | Beat |
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million